BERLIN, Oct. 5, 2006 (PRIMEZONE) -- Jerini AG (FSE:JI4) announced today that Dr. Jochen Knolle, Chief Scientific Officer and Head of R&D at Jerini, and Dr. Adi Hoess, Chief Commercial Officer at Jerini, along with hereditary angioedema (HAE) medical specialists Dr. Werner Aberer (Graz, Austria), Dr. Marco Cicardi (Milan, Italy), and Michel Raguet (HAE patient organization in France) will hold a press conference on October 6, 2006, at 10:00 a.m. (EEST) in Rhodes, Greece. The press conference will give an overview of the genetic disease HAE and outline top line results of Jerini’s recently completed Phase III clinical trials of Icatibant in the treatment of HAE.
